Literature DB >> 22993152

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

José M Martinez-Navio1, Ronald C Desrosiers.   

Abstract

Extensive glycosylation of the envelope spikes of human and simian immunodeficiency virus (HIV and SIV) is an important factor for the resistance of these viruses to neutralization by antibodies. SIVmac239 gp41 has three closely spaced sites for N-linked carbohydrate attachment. Rhesus macaques experimentally infected with mutant versions of SIVmac239 lacking two or three of these carbohydrate sites developed strong serum reactivity against mutated peptide sequences at the site of these glycosylations, as well as high titers of neutralizing activity to the mutant viruses (E. Yuste et al., J. Virol. 82:12472-12486, 2008). However, whether antibodies that recognize these underlying peptides have neutralizing activity has not been directly demonstrated. Here we describe the isolation and characterization of three gp41-specific monoclonal antibodies (4G8, 6G8, and 7D6) from one of these mutant-infected monkeys. All three antibodies reacted with mutant gp41 from viral particles and also with peptides corresponding to mutated sequences. Slight differences in peptide specificities were observed among the three antibodies. Sequence analysis revealed that the heavy chains of all three antibodies were derived from the same germ line heavy-chain segment (IGHV4-59*01), but they all had very different sequences in complementarity-determining region 3. The light chains of all three antibodies were very closely related to one another. All three antibodies had neutralizing activity to mutant viruses deficient in gp41 carbohydrate attachment, but they did not neutralize the parental SIVmac239. These results demonstrate unambiguously that antibodies with specificity for peptide sequences underlying gp41 carbohydrates can effectively neutralize SIV when these carbohydrates are absent. However, the presence of these gp41 carbohydrates effectively shields the virus from antibodies that would otherwise neutralize viral infectivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993152      PMCID: PMC3497684          DOI: 10.1128/JVI.01959-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities.

Authors:  J L Xu; M M Davis
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

2.  IMGT gene identification and Colliers de Perles of human immunoglobulins with known 3D structures.

Authors:  Manuel Ruiz; Marie-Paule Lefranc
Journal:  Immunogenetics       Date:  2002-01-30       Impact factor: 2.846

3.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 5.  Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization.

Authors:  Cheryl A Pikora
Journal:  Curr HIV Res       Date:  2004-07       Impact factor: 1.581

6.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions.

Authors:  Franco Scinicariello; Carrie N Engleman; Lakshmi Jayashankar; Harold M McClure; Roberta Attanasio
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

8.  Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.

Authors:  Welkin E Johnson; Hannah Sanford; Linda Schwall; Dennis R Burton; Paul W H I Parren; James E Robinson; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties.

Authors:  Christelle Pommié; Séverine Levadoux; Robert Sabatier; Gérard Lefranc; Marie-Paule Lefranc
Journal:  J Mol Recognit       Date:  2004 Jan-Feb       Impact factor: 2.137

10.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

Authors:  Elisabetta Traggiai; Stephan Becker; Kanta Subbarao; Larissa Kolesnikova; Yasushi Uematsu; Maria Rita Gismondo; Brian R Murphy; Rino Rappuoli; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  5 in total

1.  Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.

Authors:  James M Termini; Elizabeth S Church; Zachary A Silver; Stuart M Haslam; Anne Dell; Ronald C Desrosiers
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

2.  Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.

Authors:  Eden P Go; Alon Herschhorn; Christopher Gu; Luis Castillo-Menendez; Shijian Zhang; Youdong Mao; Haiyan Chen; Haitao Ding; John K Wakefield; David Hua; Hua-Xin Liao; John C Kappes; Joseph Sodroski; Heather Desaire
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

Review 3.  Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.

Authors:  Joern E Schmitz; Birgit Korioth-Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

4.  Neutralization function affected by single amino acid replacement in the HIV-1 antibody targets.

Authors:  Johnson Christdas; Prabu Manoharan; Shakila Harshavardhan
Journal:  Bioinformation       Date:  2015-02-28

5.  Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Desiree E Mendes; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.